Excision repair cross-complementing rodent repair deficiency gene 2 expression and chloroethylnitrosourea resistance in human glioma cell lines

Neurosurgery

Volumn 42, Issue 5, 1998, Pages 1112-1119

  Chen, Zhong Ping ^a,b   McQuillan, Angela ^b   Mohr, Gérard ^a   Panasci, Lawrence C ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Drug resistance; ERCC2; Glioma; Reverse transcription polymerase chain reaction

Indexed keywords

(2 CHLOROETHYL) 3 SARCOSINAMIDE 1 NITROSOUREA; ANTINEOPLASTIC AGENT; CARMUSTINE; CHLOROETHYLNITROSOUREA; COMPLEMENTARY DNA; NITROSOUREA DERIVATIVE; RNA; UNCLASSIFIED DRUG;

ARTICLE; BRAIN TUMOR; CANCER CHEMOTHERAPY; DRUG CYTOTOXICITY; EXCISION REPAIR; GENE EXPRESSION; GLIOMA; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

BRAIN NEOPLASMS; CARMUSTINE; COLORIMETRY; DNA HELICASES; DNA REPAIR; DNA, NEOPLASM; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC COMPLEMENTATION TEST; GLIOMA; HUMANS; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; PROTEIN BIOSYNTHESIS; PROTEINS; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 0031968946     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006123-199805000-00094     Document Type: Article

References (51)

1. Aboussekhra A, Wood RD: Repair of UV-damaged DNA by mammalian cells and Saccharomyces cerevisiae. Curr Opin Genet Dev 4:212-220, 1994.
2. Anderson BS, Sadeghi T, Siciliano MJ, Legerski R, Murray D: Nucleotide excision repair genes as determinants of cellular sensitivity to cyclophosphamide analogs. Cancer Chemother Pharmacol 38:406-416, 1996.
3. Blomgren H: Brain tumor. Acta Oncol 35[Suppl 7]:16-21, 1996.
4. 6-methylguanine-DNA methyltransferase to resistance to 1,3-(2-chloroethyl)1-nitrosourea in human brain tumor-derived cell lines. Mol Carcinog 13:81-88, 1995.
5. 6-alkylguanine in mammalian cells. J Cell Sci [Suppl 6]:147-160, 1987.
6. 6-alkylguanine-DNA alkyltransferase activity correlates with the therapeutic response of human rhabdomyosarcoma xenografts to 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea. Proc Natl Acad Sci USA 82:2985-2989, 1985.
7. Bronstein SM, Cochrane JE, Craft TR, Swenburg JA, Skopek TR: Toxicity, mutagenicity, and mutational spectra of N-ethyl-N-nitrosourea in human cell lines with different repair phenotypes. Cancer Res 51:5188-5197, 1991.
8. 6-alkylguanine-DNA alkyltransferase and nucleotide excision repair activities in human cells. Cancer Res 52: 2008-2011, 1992.
9. Chen Z-P, Malapetsa A, Marcantonio D, Mohr G, Brien S, Panasci LC: Correlation of chloroethylnitrosourea resistance with ERCC-2 expression in human tumor cell lines as determined by quantitative competitive polymerase chain reaction. Cancer Res 56:2475-2478, 1996.
10. Chen Z-P, Malapetsa A, McQuillan A, Marcantonio D, Bello V, Mohr G, Remack J, Brent TP, Panasci LC: Evidence for nucleotide excision repair as a modifying factor of MGMT mediated innate chloroethylnitrosourea resistance in human tumor cell lines. Mol Pharmacol 52:815-820, 1997.
11. Chen Z-P, Malapetsa A, Mohr G, Brien S, Panasci LC: Quantitation of ERCC-2 gene expression in human tumor cell lines by reverse transcription-polymerase chain reaction in comparison to northern blot analysis. Anal Biochem 244:50-54, 1997.
12. Chu G: Cellular responses to cisplatin: The roles of DNA-binding proteins and DNA repair. J Biol Chem 269:787-790, 1994.
13. Dabholkar MD, Berger MS, Vionnet JA, Egwuagu C, Silber JR, Yu JJ, Reed E: Malignant and nonmalignant brain tissues differ in their messenger RNA expression patterns for ERCC1 and ERCC2. Cancer Res 55:1261-1266, 1995.
14. Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E: ERCC-1 and ERCC-2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 84:1512-1517, 1992.
15. Drapkin R, Le Roy G, Cho H, Akoulitchev S, Reinberg D: Human cyclin-dependent kinase-activating kinase exists in three distinct complexes. Proc Natl Acad Sci U S A 93:6488-6493, 1996.
16. Eagan RT, Scott M: Evaluation of prognostic factors in chemotherapy of recurrent brain tumors. J Clin Oncol 1:38-44, 1983.
17. Feun LG, Savaraj N, Landy HJ: Drug resistance in brain tumors. J Neurooncol 20:165-176, 1994.
18. Flejter WL, McDaniel LD, Johns D, Friedberg EC, Schultz RA: Correction of xeroderma pigmentosum complementation group D mutant cell phenotypes by chromosome and gene transfer: Involvement of the human ERCC2 DNA repair gene. Proc Natl Acad Sci U S A 89:261-265, 1992.
19. Friedberg EC: Xeroderma pigmentosum, Cockayne's syndrome, helicases, and DNA repair: What's the relationship? Cell 71:887-889, 1992.
20. Gilliland G, Perrin S, Blanchard K, Bunn HF: Analysis of cytokine mRNA and DNA: Detection and quantitation by competitive polymerase chain reaction. Proc Natl Acad Sci U S A 87:2725-2729, 1990.
21. 6-methylguanine-DNA methyltransferase and chloroethylnitrosourea-treated DNA. Cancer Res 52:6052-6058, 1992.
22. Hayes JD, Pulford DJ: The glutathione S-transferase supergene family: Regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 30:445-600, 1995.
23. Lehmann AR: Workshop on eukaryotic DNA repair genes and gene products. Cancer Res 55:968-970, 1995.
24. Liang BC, Ross DA, Reed E: Genomic copy number changes of DNA repair genes ERCC1 and ERCC2 in human gliomas. J Neurooncol 26:17-23, 1995.
25. Lu H, Zawel L, Fisher L, Egly JM, Reinberg D: Human general transcription factor IIH phosphorylates the C-terminal domain of RNA-polymerase II. Nature 358:641-645, 1992.
26. Lunsford LD, Somaza S, Kondziolka D, Flickinger JC: Brain astocytomas: Biopsy, then irradiation. Clin Neurosurg 42:464-479, 1995.
27. Ma L, Hoeijmakers JHJ, van der Eb AJ: Mammalian nucleotide excision repair. Biochim Biophys Acta 1242:137-164, 1995.
28. Marcantonio D, Panasci LC, Hollingshead MG, Alley MC, Camalier RF, Sausville EA, Dykes DJ, Carter CA, Malspeis L: SarCNU, a novel chloroethylnitrosourea analogue with enhanced antitumor activity against human glioma xenografts. Cancer Res 57:3895-3898, 1997.
29. Marinoni JC, Roy R, Vermeulen W, Miniou P, Lutz Y, Weeda G, Seroz T, Gomez DM, Hoeijmakers JHJ, Egly JM: Cloning and characterization of p52, the fifth subunit of the core of the transcription/DNA repair factor TFIIH. EMBO J 16:1093-1102, 1997.
30. Matsumoto T, Tani E, Yamaura I, Miyaji K, Kaba K: Effects of protein kinase C modulators on multidrug resistance in human glioma cells. Neurosurgery 36:565-571, 1995.
31. Nabors MW, Griffin CA, Zehnbauer BA, Hruban RH, Phillips PC, Grossman SA, Brem H, Colvin OM: Multidrug resistance gene (MDR1) expression in human brain tumors. J Neurosurg 75:941-946, 1991.
32. Deleted in proof.
33. 6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: A phase I trial. Cancer Res 52:2456-2459, 1992.
34. Phillips PC: Antineoplastic drug resistance in brain tumors. Neurol Clin 9:383-404, 1991.
35. Ponte P, Ng S-Y, Engel J, Gunning P, Kedes L: Evolutionary conservation in the untranslated regions of actin mRNAs: DNA sequence of a human beta-actin cDNA. Nucleic Acids Res 12: 1687-1696, 1984.
36. Quigley MR, Flores N, Maroon JC, Sargent B, Lang S, Elrifai A: Value of surgical intervention in the treatment of glioma. Stereotact Funct Neurosurg 65:171-175, 1995.
37. 6-methylguanine-DNA methyltransferase. Nucleic Acids Res 11: 7743-7758, 1983.
38. Schaeffer L, Moncollin V, Roy R, Staub A, Mezzina M, Sarasin A, Weeda G, Hoeijmakers JHJ, Egly JM: The ERCC2/DNA repair protein is associated with the class II BTF2/TFIIH transcription factor. EMBO J 13:2388-2392, 1994.
39. Schaeffer L, Roy R, Humbert S, Moncollin V, Vermeulen W, Hoeijmakers JHJ, Chambon P, Egly JM: DNA repair helicase: A component of BTF2 (TFIIH) basic transcription factor. Science 260:58-63, 1993.
40. 6-methylguanine in DNA to inactivation by alkylating agents including chloroethylnitrosourea. Cancer Res 44:2467-2474, 1984.
41. Sitaram A, Plitas G, Wang W, Scicchitano DA: Functional nucleotide excision repair is required for the preferential removal of N-ethylpurines from the transcribed strand of the dihydrofolate reductase gene of Chinese hamster ovary cells. Mol Cell Biol 17:564-570, 1997.
42. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenneyand S, Boyd MR: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107-1112, 1990.
43. Sung P, Bailly V, Weber C, Thompson LH, Prakash L, Prakash S: Human xeroderma pigmentosum group D gene encodes a DNA helicase. Nature 365:852-855, 1993.
44. Sung P, Watkins JF, Prakash L, Prakash S: Negative superhelicity promotes ATP-dependent binding of yeast RAD3 protein to ultraviolet-damaged DNA. J Biol Chem 269:8303-8308, 1994.
45. Tew KD, Monks A, Barone L, Rosser D, Akerman G, Montali JA, Wheatley JB, Schmidt DE Jr: Glutathione-associated enzymes in the human cell lines of the National Cancer Institute drug screening program. Mol Pharmacol 50:149-159, 1996.
46. van Vuuren AJ, Vermeulen W, Ma L, Weeda G, Appeldoorn E, Jaspers NGJ, van der Eb AJ, Bootsma D, Hoeijmakers JHJ, Humbert S, Schaeffer L, Egly JM: Correction of xeroderma pigmentosum repair defect by basal transcription factor BTF2 (TFIIH). EMBO J 13:1645-1653, 1994.
47. Walker MD: Chemotherapy: Adjuvant to surgery and radiation therapy. Semin Oncol 2:69-72, 1975.
48. Walker MD, Green SB, Byar OP, Alexander E Jr, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Owens G, Ransohoff J II, Robertson JT, Shapiro WR, Smith KR Jr, Wilson CB, Strike TA: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323-1329, 1980.
49. Weber CA, Salazar EP, Stewart SA, Thompson LH: Molecular cloning and biological characterization of a human gene, ERCC-2, that corrects the nucleotide excision repair defect in CHO UV5 cells. Mol Cell Biol 8:1137-1146, 1988.
50. Xue Y, Nicholson WL: The two major spore DNA repair pathways, nucleotide excision repair and spore photoproduct lyase, are sufficient for the resistance of Bacillus subtilis spores to artificial UV-C and UV-B but not to solar radiation. Appl Environ Microbiol 62:2221-2227, 1996.
51. Zeng-Rong N, Paterson J, Alpert L, Tsao M-S, Viallet J, Alaoui-Jamali MA: Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy. Cancer Res 55:4760-4764, 1995.